Cybin expands clinical team to support cyb003 phase 3 program

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the appointment of senior clinical team leaders, dr. mirza rahman as senior vice president, patient safety & pharmacovigilance and dr. marcelo gutierrez, vice president, clinical pharmacology, as well as the e.
CYBN Ratings Summary
CYBN Quant Ranking